All looks good........
- double digit growth across all metrics
- 1.1M customers using the platform
- cash burn to slow after this HY
- etc
They have mentioned previously the initial target market with the JV with Zuellig is Philippines (27,000 pharmacies) and South Korea (21,000 pharmacies).
There are ~5500 pharmacies in Australia. Just those two countries is 9 times larger than Australia's market .... and this is the initial launch.
The population and healthcare sizes of Singapore, Malaysia, India (plus others) is not included.
MedAdvisor expects to turn the MOU binding with the long form agreement in Q3FY19, so next month.
One thing I did notice and have observed in previous announcements is the lack of excitement around PDX (US).
They are not even mentioned by name in this announcement.
Still, I'm excited to see the growth in the business with increased revenue, new appointments and international compliance.
EBOS might also see some return on their multi-million dollar investment which occurred at 5.75c.
Ann: MDR H1 FY2019 Financial Report & Appendix 4D, page-2
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.0¢ |
Change
-0.010(1.82%) |
Mkt cap ! $297.2M | |||
| Open | High | Low | Value | Volume |
| 53.5¢ | 54.5¢ | 51.0¢ | $105.8K | 202.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3780 | 52.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 9069 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MDR (ASX) Chart |